These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34767140)

  • 1. Risk factors for failure of long-term dutasteride add-on treatment to alpha-adrenergic antagonist for patients with lower urinary tract symptoms and benign prostatic enlargement.
    Wada N; Abe N; Miyauchi K; Ishikawa M; Makino S; Kakizaki H
    Int Urol Nephrol; 2022 Jan; 54(1):31-36. PubMed ID: 34767140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride.
    Yoshida T; Kinoshita H; Yoshida K; Mishima T; Taniguchi H; Yanishi M; Komai Y; Yasuda K; Sugi M; Matsuda T
    Urology; 2016 May; 91():154-7. PubMed ID: 26826590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dutasteride add-on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alpha-adrenergic antagonist monotherapy: A single center prospective study.
    De Nunzio C; Brassetti A; Proietti F; Gacci M; Serni S; Esperto F; Tubaro A
    Neurourol Urodyn; 2017 Nov; 36(8):2096-2100. PubMed ID: 28257560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
    Wada N; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study.
    Matsukawa Y; Kato M; Funahashi Y; Majima T; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2017 Sep; 36(7):1809-1815. PubMed ID: 28102554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Low Urin Tract Symptoms; 2015 Jan; 7(1):37-41. PubMed ID: 26663650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.
    Gravas S; Palacios-Moreno JM; Thompson D; Concas F; Kamola PJ; Roehrborn CG; Oelke M; Kattan MW; Averbeck MA; Manyak M; Cortés V; Lulic Z
    Eur Urol Focus; 2023 Jan; 9(1):178-187. PubMed ID: 35985933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
    Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dutasteride add-on treatment to tadalafil for patients with benign prostatic enlargement is similarly effective as dutasteride add-on treatment to alpha blocker: a propensity-score matching analysis.
    Wada N; Abe N; Miyauchi K; Ishikawa M; Makino S; Kakizaki H
    Int Urol Nephrol; 2022 Jun; 54(6):1193-1198. PubMed ID: 35362820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
    D'Agate S; Chavan C; Manyak M; Palacios-Moreno JM; Oelke M; Michel MC; Roehrborn CG; Della Pasqua O
    World J Urol; 2021 Jul; 39(7):2635-2643. PubMed ID: 33337513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of 5-reductase inhibitors in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia].
    Nizov AN
    Urologiia; 2019 Dec; (5):156-160. PubMed ID: 31808653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open-label, multicenter study.
    Matsumoto T; Hatakeyama S; Narita T; Yoneyama T; Hashimoto Y; Ohyama C
    Int J Urol; 2019 Apr; 26(4):522-523. PubMed ID: 30659664
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
    Matsukawa Y; Ishida S; Majima T; Funahashi Y; Sassa N; Kato M; Yoshino Y; Gotoh M
    Int J Urol; 2017 Jun; 24(6):454-459. PubMed ID: 28370376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.
    Shindo T; Hashimoto K; Shimizu T; Itoh N; Masumori N
    Korean J Urol; 2015 Apr; 56(4):305-9. PubMed ID: 25874044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Intravesical Prostatic Protrusion as a Predictor of Dutasteride-Resistant Lower Urinary Tract Symptoms/Benign Prostatic Enlargement With a High Likelihood of Surgical Intervention.
    Hirayama K; Masui K; Hamada A; Shichiri Y; Masuzawa N; Hamada S
    Urology; 2015 Sep; 86(3):565-9. PubMed ID: 26199172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.